Article Text

other Versions

Ovarioleukodystrophy due to EIF2B5 mutations
  1. R T Ibitoye1,
  2. S A Renowden2,
  3. H J Faulkner1,
  4. N J Scolding1,
  5. C M Rice1
  1. 1Department of Neurology, Southmead Hospital, Bristol, UK
  2. 2Department of Neuroradiology, Southmead Hospital, Bristol, UK
  1. Correspondence to Dr Richard T Ibitoye, Department of Neurology, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK; richard.ibitoye{at}


Ovarioleukodystrophy—the co-occurrence of leukodystrophy and premature ovarian failure—is a rare presentation now recognised to be part of the clinical spectrum of vanishing white matter disease. We describe a woman with epilepsy and neuroimaging changes consistent with leukoencephalopathy who presented with non-convulsive status epilepticus after starting hormone replacement therapy in the context of premature ovarian failure. Genetic testing confirmed her to be a compound heterozygote for EIF2B5 mutations; the gene encodes a subunit of eukaryotic translation initiation factor 2B. Mutations in EIF2B1–5 result in vanishing white matter disease. We highlight the importance of ovarian failure as a diagnostic pointer to eukaryotic translation initiation factor 2B (eIF2B)-related ovarioleukodystrophy and present a brief literature review of ovarioleukodystrophy.

  • vanishing white matter
  • ovarioleukodystrophy
  • VWM
  • EIF2B

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editors' commentary
    Phil E M Smith Geraint N Fuller